Home/Pipeline/ultraIPV

ultraIPV

Polio Prevention

Pre-clinicalActive

Key Facts

Indication

Polio Prevention

Phase

Pre-clinical

Status

Active

Company

Biological Mimetics

About Biological Mimetics

Biological Mimetics is a private, pre-revenue biotechnology company with a 25+ year history, specializing in novel vaccine and diagnostic platforms. Its lead technologies include IRT (Immune Refocusing Technology) for creating more broadly protective vaccines and MDP (Manganese-Decapeptide-Phosphate) for pathogen inactivation, with an advanced program in ultraIPV (inactivated polio vaccine). The company also collaborates on FAST, a portable CRISPR-based diagnostic tool designed for low-resource settings. BMI operates through partnerships to advance its platforms toward the market.

View full company profile

Therapeutic Areas

Infectious Disease

Other Polio Prevention Drugs

Drug	Company	Phase	Status
Dose-Sparing Inactivated Polio Vaccine (IPV)	AJ Vaccines	Commercial	Active
Sabin IPV (sIPV) Process Development	Batavia Biosciences	Development/Commercial	Active